NewAmsterdam Pharma Company (NAMS) Jefferies 2024 Global Healthcare Conference summary

Company vision and lead asset

• Focused on the cardiometabolic space with lead asset obicetrapib, a CETP inhibitor in multiple phase III studies.

• Obicetrapib has shown consistent LDL reduction of up to 40% in phase II studies, with additional benefits beyond LDL lowering.

• Over 30 million Americans have elevated LDL despite available treatments, indicating significant market opportunity.

Clinical development and upcoming catalysts

• Conducting four major phase III studies, with two key data readouts expected in the second half of 2024: BROOKLYN (FH) in Q3 and BROADWAY (ASCVD) in Q4.

• Both studies will report 12-week and 52-week LDL reduction data, along with safety insights.

• BROOKLYN targets highly motivated FH patients, with low dropout rates and high compliance.

• Phase II and III studies aim to replicate strong efficacy and placebo-like safety profile seen in earlier trials.

Cardiovascular outcomes trial (PREVAIL)

• PREVAIL CVOT completed enrollment above target with over 9,500 patients; data expected by late 2026.

• Minimum 2.5-year follow-up, with median follow-up approaching 3.5-4 years.

• Designed to enroll patients with higher baseline LDL and risk enhancers like diabetes, while excluding heart failure patients.

• No interim analysis; FDA requires full follow-up to avoid premature data disclosure.